Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hodgkin Disease 2Hematologic Neoplasms 2Sezary Syndrome 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Cytomegalovirus Infections 1

Interventions

Cyclophosphamide 41Peripheral Blood Stem Cell Transplantation 40fludarabine phosphate 36Whole-Body Irradiation 27Mycophenolic Acid 27Tacrolimus 23Busulfan 23Cyclosporine 22Antilymphocyte Serum 20Etoposide 17Methotrexate 16Filgrastim 16Melphalan 14romidepsin 13Radiotherapy 13Flow Cytometry 12Methylprednisolone 10Brentuximab Vedotin 10Therapeutics 9Psychiatric Rehabilitation 9Lenalidomide 8pembrolizumab 7fludarabine 7Sirolimus 7Rituximab 7Bortezomib 7Bexarotene 7mogamulizumab 6Polymerase Chain Reaction 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Cutaneous × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡